Literature DB >> 1703599

Electrophysiological properties of SD-3211, a novel putative Ca2+ antagonist, in isolated guinea pig and rabbit hearts.

N Miyawaki1, T Furuta, T Shigei, H Yamauchi, T Iso.   

Abstract

The cardiac effects of SD-3211, a novel non-dihydropyridine type of Ca2+ antagonist, were examined in isolated guinea pig and rabbit hearts using an electrophysiological technique. SD-3211 (10(-6)-10(-5) M) shortened the action potential duration of guinea pig papillary muscles in a concentration-dependent manner without affecting the resting potential or the maximum upstroke velocity (Vmax). The Vmax of slow responses induced by high extracellular K+ and isoproterenol was inhibited by SD-3211 at concentrations of greater than 10(-6) M. Elevation of extracellular Ca2+ by 2 mM reversed this inhibited response. The inhibitory effect of SD-3211 on the slow response was enhanced as the stimulation frequency was increased. In Langendorff-perfused rabbit hearts electrically driven at 2.0 Hz, SD-3211 (10(-8)-10(-6) M) produced a concentration-dependent prolongation of the atrium-His bundle conduction time (A-H interval) as well as a reduction in the developed tension of ventricular muscle, whereas SD-3211 did not affect the His bundle-ventricular conduction time (H-V interval) significantly. The potency of SD-3211 in A-H prolongation was greater than those of diltiazem and bepridil, but weaker than those of nicardipine, nifedipine, and verapamil. The effect of SD-3211 on the A-H interval was more pronounced at higher stimulation frequencies. SD-3211 was intermediate between nicardipine and verapamil in its intensity of frequency-dependent effects on the A-H interval. These results suggest that SD-3211 has a preferential and frequency-dependent inhibitory action on cardiac slow Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1703599     DOI: 10.1097/00005344-199011000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Antiarrhythmic effects of a benzothiazine derivative (SD-3211) and its stereoisomer (SA3212) in anaesthetized rats and isolated perfused rat hearts compared with bepridil.

Authors:  M Fukuchi; T Uematsu; S Nagashima; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

2.  Electrophysiological effects of SD-3212, a new antiarrhythmic agent with vasodilator action, on guinea-pig ventricular cells.

Authors:  I Kodama; R Suzuki; K Maruyama; J Toyama
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

3.  Semotiadil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.

Authors:  T Takahashi; T Kanda; S Imai; T Suzuki; I Kobayashi; K Murata
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

4.  Antiarrhythmic and electrophysiological effects of SD-3212, a novel Na+ and Ca++ channel blocker, in anaesthetized dogs with myocardial infarction in comparison with its stereoisomer (SD-3211) and bepridil.

Authors:  S Nagashima; T Uematsu; S Araki; T Matsuzaki; M Fukuchi; H Hashimoto; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

5.  SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells.

Authors:  Y Hara; H Nakaya
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

6.  Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model.

Authors:  T Mori; Y Ishigai; A Fukuzawa; K Chiba; T Shibano
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

7.  Effects of semotiadil fumarate, a novel Ca2+ antagonist, on cytosolic Ca2+ level and force of contraction in porcine coronary arteries.

Authors:  M Kageyama; T Yanagisawa; N Taira
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.